Explore

Nanorobotics Market Projected to Reach $31.44 Billion by 2034 Amidst Growth in Precision Medicine

Nanorobotics Market Projected to Reach $31.44 Billion by 2034 Amidst Growth in Precision Medicine

The global nanorobotics market is projected to reach USD 31.44 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 14.9% during the forecast period of 2026-2034, according to a new report by Polaris Market Research. The market, valued at USD 9.01 billion in 2025, is experiencing steady growth driven by the increasing adoption of precision medicine, rising investment in nanomedicine research, and continuous advancements in nano-engineering. Key applications include targeted drug delivery systems, regenerative medicine platforms, and minimally invasive treatment technologies. North America held the largest revenue share in 2025, accounting for approximately 40.9%, primarily due to strong funding for nanomedicine research and advanced healthcare infrastructure. Microbivore nanorobots led the type segment in 2025, while cell-repair nanorobots are expected to see the fastest expansion. Drug delivery remains the largest application segment, with regenerative medicine applications forecasted for r...

Quel Health Launches Telehealth Platform for Addiction Treatment Using GLP-1 Medications

Quel Health Launches Telehealth Platform for Addiction Treatment Using GLP-1 Medications

Santa Fe, N.M.-based startup Quel Health has launched a new telehealth platform designed for addiction treatment, notably incorporating GLP-1 medications. The company asserts this is the first national telehealth service of its kind to utilize GLP-1s for this purpose. The platform offers patients video evaluations, individualized treatment plans, and ongoing care support from affiliated providers. While providers may prescribe GLP-1s off-label when clinically appropriate, it's important to note that the U.S. Food and Drug Administration (FDA) has not yet approved these medications for substance use indications. Over 50 clinical trials are currently registered on ClinicalTrials.gov to examine the use of GLP-1s for addiction. Quel Health was co-founded by epidemiologist Marlene C. Lira and physician-scientist Steven D. Klein, M.D., Ph.D., aiming to provide an accessible, private, and human-centered approach to what they term 'dopamine health.' The platform is currently available in 41 states and Washington, ...

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics plc, a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel). This designation is specifically for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The RMAT designation is a program established under the 21st Century Cures Act, designed to expedite the development and regulatory review process for regenerative medicine therapies, including cell therapies, that are intended to treat serious or life-threatening diseases. Autolus Therapeutics is currently enrolling patients in LUMINA, a pivotal Phase 2 study for obe-cel in refractory lupus nephritis, and expects to report data in 2028. The company also submitted a data update from the Phase 1 CARLYSLE trial for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026.

Ridge Biotechnologies Secures Additional Investment to Advance AI-Designed Bioconjugate Therapeutics

Ridge Biotechnologies Secures Additional Investment to Advance AI-Designed Bioconjugate Therapeutics

Ridge Biotechnologies Secures Additional Investment to Advance AI-Designed Bioconjugate Therapeutics

Novo Nordisk Halts Two Phase 3 Studies for Heart Failure Drug Ziltivekimab Following Disappointing ZEUS Trial Results

Novo Nordisk Halts Two Phase 3 Studies for Heart Failure Drug Ziltivekimab Following Disappointing ZEUS Trial Results

Novo Nordisk Halts Two Phase 3 Studies for Heart Failure Drug Ziltivekimab Following Disappointing ZEUS Trial Results

Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine is advancing towards a first-in-human study for EDIT-401, an in vivo CRISPR-edited medicine designed to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia. According to CEO Gilmore O’Neill, the company is focused on in vivo CRISPR-edited medicines that offer differentiated efficacy and utilize gene-editing capabilities. EDIT-401 aims to increase the production of LDL receptors in liver cells, thereby enhancing the removal of LDL cholesterol from the bloodstream. Preclinical findings in non-human primates showed a mean reduction of 90% in LDL cholesterol, lipoprotein(a), and apolipoprotein B. The treatment is designed as a single intravenous infusion. Editas Medicine has submitted documentation to human research ethics committees in Australia and plans to dose the first patients this year. The Phase 1 trial will involve serial dose-escalation cohorts and an expansion into a broader patient population. The company anticipates sharing safety data in the first qu...

Tulane University Study Suggests Weight-Loss Drug Semaglutide May Treat Lymphedema

Tulane University Study Suggests Weight-Loss Drug Semaglutide May Treat Lymphedema

A recent study conducted by Tulane University researchers has found that semaglutide, a popular weight-loss drug belonging to the GLP-1 class of medications, may also be effective in treating lymphedema. Lymphedema is a chronic and debilitating disease characterized by swelling, primarily in the limbs, due to an improperly draining lymphatic system. The study, published in the journal Microcirculation, revealed that semaglutide can widen vessels within the lymphatic system, thereby enhancing their ability to move larger quantities of fluid with each contraction. This research is significant as it marks the first time GLP-1 receptors have been identified in lymphatic vessels. Lymphedema affects over 250 million people globally, with secondary lymphedema, often a consequence of cancer treatment or obesity, being the most common form in the U.S. The findings suggest a potential new therapeutic avenue for a condition that currently lacks approved drug therapies.

Alzheon Publishes Peer-Reviewed Data on Oral Valiltramiprosate for Early Alzheimer's Disease

Alzheon Publishes Peer-Reviewed Data on Oral Valiltramiprosate for Early Alzheimer's Disease

Alzheon, Inc., a clinical-stage biopharmaceutical company, has announced the peer-reviewed publication of data from its Phase 3 APOLLOE4 trial and a four-year Phase 2 study in the journal *Drugs*. The publication details the effects of oral valiltramiprosate (ALZ-801) on plasma biomarkers in patients with early Alzheimer's disease (AD), particularly those who are APOE4 carriers. The studies demonstrated that valiltramiprosate achieved early and sustained reductions in key blood-based biomarkers, including plasma p-tau217 and the p-tau217/Aβ42 ratio. These reductions correlated with better cognitive, functional, and brain atrophy outcomes. According to Martin Tolar, Founder, President, and CEO of Alzheon, valiltramiprosate has shown potential to meaningfully change Alzheimer's therapy by targeting the amyloid cascade and inhibiting the formation of neurotoxic soluble amyloid oligomers. The drug maintained a favorable safety profile, with no increase in ARIA-E (amyloid-related imaging abnormalities with edem...

Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial, Expanding Market Potential

Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial, Expanding Market Potential

Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial, Expanding Market Potential

GLP-1 Medications Show Promise in Treating Opioid Addiction, Caron Treatment Centers Lead Off-Label Prescriptions

GLP-1 Medications Show Promise in Treating Opioid Addiction, Caron Treatment Centers Lead Off-Label Prescriptions

GLP-1 medications, primarily known for their role in weight-loss management and diabetes treatment, are now being explored for their potential in treating opioid addiction. Dr. Adam Scioli, formerly the chief medical officer and an addictions psychiatrist at Caron Treatment Centers in the United States, has been a key figure in this development. Caron Treatment Centers began prescribing GLP-1s off-label for substance-use disorders in 2024 and has since administered them to over 500 residential clients. While researchers initially cautioned against this approach, Dr. Scioli and his colleagues stand by their decision, citing observed benefits. Early research suggests that GLP-1s may help reduce drug cravings by impacting the brain's dopamine pathway, which is central to both hunger and addiction. Studies, including one at a Caron treatment center, have shown a significant reduction in opioid cravings among participants receiving GLP-1 drugs.

GLP-1 Weight-Loss Drugs Show Promise in Treating Obesity-Related Sleep Apnea

GLP-1 Weight-Loss Drugs Show Promise in Treating Obesity-Related Sleep Apnea

A recent review published in JAMA Otolaryngology indicates that GLP-1 weight-loss drugs, such as tirzepatide (marketed as Zepbound and Mounjaro), can significantly reduce the severity of obesity-related obstructive sleep apnea (OSA). Clinical trials included in the review demonstrated that individuals taking tirzepatide experienced 20 to 24 fewer breathing interruptions per hour compared to those on a placebo. Nearly half of the participants achieved remission from OSA. Researchers from the University of Pittsburgh Medical Center suggest that the primary mechanism behind this improvement is weight loss, specifically the reduction of fat in the tongue and around the throat, which helps maintain an open airway during sleep. Obesity is a major contributing factor in most OSA cases, and until recently, no medication directly addressed this aspect of the condition. The U.S. Food and Drug Administration approved Zepbound for moderate to severe OSA in adults with obesity in 2024.

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost